Hollis, Robert L. http://orcid.org/0000-0002-1390-3298
Croy, Ian
Churchman, Michael
Bartos, Clare
Rye, Tzyvia
Gourley, Charlie
Herrington, C. Simon http://orcid.org/0000-0001-9177-8165
Funding for this research was provided by:
Tenovus Scotland (ref E19-11) The Nicola Murray Foundation
Cancer Research UK
Article History
Received: 1 February 2022
Revised: 18 May 2022
Accepted: 30 May 2022
First Online: 17 June 2022
Competing interests
: RLH: consultancy fees from GSK outside the scope of this work. IC: none. MC: none. TR: none. CB: none. CG: CG: grants from AstraZeneca, MSD, BMS, Clovis, Novartis, BerGenBio, Medannexin and Artios; personal fees from AstraZeneca, MSD, GSK, Tesaro, Clovis, Roche, Foundation One, Chugai, Takeda, Sierra Oncology, Takeda and Cor2Ed outside the submitted work; patents PCT/US2012/040805 issued, PCT/GB2013/053202 pending, 1409479.1 pending, 1409476.7 pending and 1409478.3 pending. CSH: none.
: Ethical approval for the study was obtained from the Lothian NRS Human Annotated Bioresource (reference 15/ES/0094-SR1330). All participants gave written informed consent or had consent waived by the ethics committee due to the retrospective nature of the study. The study was performed in accordance with the Declaration of Helsinki.
: Not applicable.